Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trials

Eur Urol. 2008 Jan;53(1):6-9. doi: 10.1016/j.eururo.2007.08.041. Epub 2007 Aug 28.
No abstract available

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Biomarkers, Tumor / blood
  • Clinical Trials as Topic*
  • Combined Modality Therapy / methods
  • Disease-Free Survival
  • Humans
  • Male
  • Prognosis
  • Prostate-Specific Antigen / blood*
  • Prostatic Neoplasms* / blood
  • Prostatic Neoplasms* / mortality
  • Prostatic Neoplasms* / therapy
  • Survival Rate

Substances

  • Biomarkers, Tumor
  • Prostate-Specific Antigen